Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival

Cancer Research

Volumn 71, Issue 13, 2011, Pages 4550-4561

  Masica, David L ^a   Karchin, Rachel ^a  

^a Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BUB3 PROTEIN; BULLOUS PEMPHIGOID ANTIGEN 1; CRK LIKE PROTEIN; E1A ASSOCIATED P300 PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPHRIN RECEPTOR B4; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FURIN; HEPSIN; KRUPPEL LIKE FACTOR 6; MITOCHONDRIAL TRANSCRIPTION FACTOR A; MITOGEN ACTIVATED PROTEIN KINASE 9; PROTEIN MDM2; PROTEIN MSH6; PROTEIN P53; RAF PROTEIN; SCATTER FACTOR RECEPTOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL M3;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE SEQUENCE; GLIOBLASTOMA; MOLECULAR INTERACTION; ONCOGENE; PREDICTION; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

ALGORITHMS; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION; GENE REGULATORY NETWORKS; GENES, P53; GENOMICS; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS;

EID: 79959873016     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0180     Document Type: Article

References (50)

1. Jones S, Zhang X, Parsons DW, Lin JC-H, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
2. McLendon R, Friedman A, Bigner D, Van Meir E, Brat D, Mastrogianakis G, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455:1061-8.
3. Yeang C-H, McCormick F, Levine A. Combinatorial patterns of somatic gene mutations in cancer. FASEB J 2008;22:2605-22.
4. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
5. Gaire RK, Bailey J, Bearfoot J, Campbell IG, Stuckey PJ, Haviv I. MIRAGAA - a methodology for finding coordinated effects of micro-RNA expression changes and genome aberrations in cancer. Bioinformatics 2010;26:161-7.
6. Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 2010;26:237-45.
7. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 2009;4:e7752.
8. Freire P, Vilela M, Deus H, Kim Y-W, Koul D, Colman H, et al. Exploratory analysis of the copy number alterations in glioblastoma multiforme. PLoS One 2008;3:e4076.
9. Cerami E, Demir E, Schultz N, Taylor BS, Sander C. Automated network analysis identifies core pathways in glioblastoma. PLoS One 2010;5:e8918.
10. Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, Renfrow JJ, et al. A network model of a cooperative genetic landscape in brain tumors. JAMA 2009;302:261-75.
11. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
12. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010;17:510-22.
13. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene Addiction. Cell 2009;136:823-37.
14. McManus KJ, Barrett IJ, Nouhi Y, Hieter P. Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing. Proc Natl Acad Sci U S A 2009;106:3276-81.
15. Ikediobi ON. Somatic pharmacogenomics in cancer. Pharmacogenomics J 2008;8:305-14.
16. Singh A, Settleman J. Oncogenic K-ras "addiction" and synthetic lethality. Cell Cycle 2009;8:2676-8.
17. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21. (Pubitemid 32397092)
18. Thaker NG, Zhang F, McDonald PR, Shun TY, Lewen MD, Pollack IF, et al. Identification of survival genes in human glioblastoma cells by small interfering RNA screening. Mol Pharmacol 2009;76:1246-55.
19. Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001;294:2563-6. (Pubitemid 34027299)
20. Jeng Y-M, Hsu H-C. KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int J Cancer 2003;105:625-9. (Pubitemid 36687729)
21. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins VP. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 2000;60:417-24. (Pubitemid 30070771)
22. Degenhardt Y, Greshock J, Laquerre S, Gilmartin AG, Jing J, Richter M, et al. Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Mol Cancer Ther 2010;9:2079-89.
23. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA, Kinzler KW, et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A 2009;106:3964-9.
24. Bonte D, Lindvall C, Liu H, Dykema K, Furge K, Weinreich MCdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation Neoplasia 2008;10:920-31.
25. Nambiar S, Mirmohammadsadegh A, Hassan M, Mota R, Marini A, Alaoui A, et al. Identification and functional characterization of ASK/Dbf4, a novel cell survival gene in cutaneous melanoma with prognostic relevance. Carcinogenesis 2007;28:2501-10. (Pubitemid 350238952)
26. Macleod K, Mullen P, Sewell J, Rabiasz G, Lawrie S, Miller E, et al. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res 2005;65:6789-800. (Pubitemid 41060717)
27. Ooe A, Kato K, Noguchi S. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers. Breast Cancer Res Treat 2007;101:305-15.
28. Yuan B, Xu Y, Woo J-H, Wang Y, Bae YK, Yoon D-S, et al. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 2006;12:405-10. (Pubitemid 43166128)
29. Ghosh JC, Dohi T, Kang BH, Altieri DC. Hsp60 regulation of tumor cell apoptosis. J Biol Chem 2008;283:5188-94.
30. Cormio A, Guerra F, Cormio G, Pesce V, Fracasso F, Loizzi V, et al. The PGC-1[alpha]-dependent pathway of mitochondrial biogenesis is upregulated in type I endometrial cancer. Biochem Biophys Res Commun 2009;390:1182-5.
31. Paterson A, Kudlow J. Regulation of glutamine:fructose-6-phosphate amidotransferase gene transcription by epidermal growth factor and glucose. Endocrinology 1995;136:2809-16.
32. Ran Y, Hu H, Hu D, Zhou Z, Sun Y, Yu L, et al. Derlin-1 is over-expressed on the tumor cell surface and enables antibody-mediated tumor targeting therapy. Clin Cancer Res 2008;14:6538-45.
33. Ho J, Kong J-W-F, Choong L-Y, Loh M-C-S, Toy W, Chong P-K, et al. Novel breast cancer metastasis-associated proteins. J Proteome Res 2008;8:583-94.
34. The Gene expression profiles of medulloblastoma cell lines resistant to preactivated cyclophosphamide. Curr Cancer Drug Targets 2008;8:172-9.
35. Kitajima S, Miki T, Takegami Y, Kido Y, Noda M, Hara E, et al. Reversion-inducing cysteine-rich protein with Kazal motifs interferes with epidermal growth factor receptor signaling. Oncogene 2011;30:737-50.
36. Hwang EY, Huh J-W, Choi M-M, Choi SY, Hong H-N, Cho S-W. Inhibitory effects of gallic acid and quercetin on UDP-glucose dehydrogenase activity. FEBS Lett 2008;582:3793-7.
37. Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res 2009;69:2065-71.
38. Flores O, Burnstein KL. GADD45{gamma}: a new vitamin D-regulated gene that is antiproliferative in prostate cancer cells. Endocrinology 2010;151:4654-64.
39. Ruckhäberle E, Karn T, Rody A, Hanker L, Gätje R, Metzler D, et al. Gene expression of ceramide kinase, galactosyl ceramide synthase and ganglioside GD3 synthase is associated with prognosis in breast cancer. J Cancer Res Clin Oncol 2009;135:1005-13.
40. Mitra P, Maceyka M, Payne SG, Lamour N, Milstien S, Chalfant CE, et al. Ceramide kinase regulates growth and survival of A549 human lung adenocarcinoma cells. FEBS Lett 2007;581:735-40. (Pubitemid 46217927)
41. Teicher BA. Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs. Current Opin Pharmac 2010;10:397-404.
42. Obara W, Tsunoda T, Yoshida K, Kanehira M, Takata R, Katagiri T, et al. Phase I/II study of novel HLA-A24 restricted DEPDC1 and MPHOSPH1 peptide vaccine for bladder cancer. In: J Clin Oncol (Meeting Abstr) 2010;28:e13122.
43. Lindsley C, Barnett S, Layton M, Bilodeau M. The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Curr Cancer Drug Targets 2008;8:7-18. (Pubitemid 351237905)
44. Antonacopoulou AG, Grivas PD, Skarlas L, Kalofonos M, Scopa CD, Kalofonos HP. POLR2F, ATP6V0A1 and PRNP expression in colorectal cancer: new molecules with prognostic significance? Anticancer Res 2008;28:1221-7.
45. Kim J, Kim H, Lee K, Lee J, Choi S, Paik S, et al. Gene expression profiles in gallbladder cancer: the close genetic similarity seen for early and advanced gallbladder cancers may explain the poor prognosis. Tumor Biol 2008;29:41-9. (Pubitemid 351733219)
46. Purow B, Schiff D. Advances in the genetics of glioblastoma: are we reaching critical mass? Nat Rev Neurol 2009;5:419-26.
47. Doherty JA, Rossing MA, Cushing-Haugen KL, Chen C, Van Den Berg DJ, Wu AH, et al. ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium Study. Cancer Epidemiol Biomarkers Prev 2010;19:245-50.
48. Ricke RM, van Ree JH, van Deursen JM. Whole chromosome instability and cancer: a complex relationship. Trends Genet 2008;24:457-66.
49. Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003;161:281-94.
50. Sugiura T, Nagano Y, Noguchi Y. DDX39, upregulated in lung squamous cell cancer, displays RNA helicase activities and promotes cancer cell growth. Cancer Biol Ther 2007;6:957.